I think the commercial success of PromarkerD in the near term is the concern, at least for me. Several failed attempts over the years, mostly due the rollout being LDT whereas IVD requires regulatory approval processes.
Feb, 2021 was when they informed the market about having a presubmission meeting with the FDA. Here we are 16months later and still no FDA submission. This is poor execution by management IMO.
Agree, it's the pipeline and intrinsic value that keeps me invested here and also why the register is fairly tight, but personally I am really reaching the end of my tether with Richard's lack of transparency and missed targets. I have been holding now for 4.5years with a bag of a quarter million shares on the promise of PromarkerD actually generating sales but it's clear now the LDT roll out strategy is not working, and then more importantly why are they stalling LDT rollout in the US? They have repeatedly said they can make use of a generic CPT codes, no FDA approval needed, what is going on there??
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)